| Status: AWMSG assessment in progress | ||
In the absence of a submission from the holder of the marketing authorisation, capsaicin (Qutenza®) cannot be endorsed for use within NHS Wales for the treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain. The AWMSG Scrutiny Panel considered Capsaicin (Qutenza®) suitable for a limited assessment which is now in progress. |
||
|
||
Medicine details |
||
| Medicine name | capsaicin (Qutenza®) | |
| Formulation | 179 mg cutaneous patch | |
| Reference number | 2889 | |
| Indication | Treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain |
|
| Company | Grünenthal Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Limited | |
| Status | AWMSG assessment in progress | |
| Scrutiny Panel meeting date | 18/12/2025 | |
| LOWMAG meeting date | 21/10/2026 | |
| AWMSG meeting date | 02/12/2026 | |
| Date of issue | SOA issued 09/12/2015 | |
| Further information The AWMSG Scrutiny Panel considered capsaicin (Qutenza®) suitable for a limited assessment at their meeting on 18/12/2025 - assessment is now in progress. |
||